Genetic data may up diagnostic efficiency for rheumatic disease

(HealthDay)—Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease, according to a study published in the May 27 issue of Science Translational Medicine. Rachel Knevel, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues developed a Genetic Probability tool (G-PROB) to calculate the probability of […]

Read more

Innovative CareView app provides patient data on 7 conditions related to 40% of ED visits

Doctors at Indiana University Health hospitals now have faster, easier access to information about the patients they are treating in the emergency department. The CareView app, created in a partnership among Regenstrief Institute, Indiana Health Information Exchange (IHIE), IU Health and Indiana University School of Medicine, provides clinicians with only the most relevant information from a patient’s medical history related […]

Read more

Tendency to correlate uptick in suicides and social media is not backed by data

Are smartphones and screen media behind the rise in adolescent suicide and dysphoria—or are economic and parental pressures just as likely contributors? The recent increases in adolescent suicide in the United States have raised concerns about the effects of heavy online screen-media use. Some researchers have suggested that the elevated suicide rate and depression among adolescents and young adults reflect […]

Read more

First comprehensive structural data on a key flu protein—it’s central to infection

Influenza A viruses spawn epidemics, global pandemics and sweeping outbreaks that kill millions of birds, yet only now have flu scientists obtained comprehensive, high-resolution structural data on a protein that is key to the very survival of an influenza virus. The highlighted protein is RNA polymerase, which transcribes and replicates the viral genome in the nucleus of host cells. Dr. […]

Read more

New data indicate rise in opioid use for migraine treatment

An increasing number of Americans are using opioids to treat their migraine headaches, despite the fact that opioids are not the recommended first-line therapy for migraine in most cases. That’s according to the ObserVational Survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) study, a web-based patient survey of people living with migraine. Migraine care specialist Sait Ashina, MD, […]

Read more

Data shows flood of opioids across US, many of them generics

The maker of OxyContin has been cast as the chief villain in the nation’s opioid crisis. But newly released government figures suggest Purdue Pharma had plenty of help in flooding the U.S. with billions of pills even as overdose deaths were accelerating. Records kept by the federal Drug Enforcement Administration show that 76 billion oxycodone and hydrocodone pills—the vast majority […]

Read more

Data show no evidence that teens’ social media use predicts depression over time

Longitudinal data from adolescents and young adults show no evidence that social media use predicts later depressive symptoms, according to research published in Clinical Psychological Science, a journal of the Association for Psychological Science. However, the findings do show that relatively higher depressive symptoms predicted later social media use among adolescent girls. This research stands in contrast with recent claims […]

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Breda, the Netherlands / Ghent, Belgium – December 03, 2018 — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced  that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)  and […]

Read more

New two-year data show 39 percent of NHL patients treated with CAR T remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive. The new long-term safety and […]

Read more
1 2